Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.04M | 4.01M | 4.74M | 1.08M | 71.00K | Gross Profit |
1.04M | 4.01M | 3.35M | -184.00K | -56.93M | EBIT |
-338.85M | -222.61M | -167.88M | -107.70M | -74.95M | EBITDA |
-338.85M | -221.51M | -166.90M | -106.78M | -72.59M | Net Income Common Stockholders |
-298.41M | -214.53M | -159.95M | -106.72M | -72.86M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
1.35B | 558.55M | 334.43M | 333.71M | 170.88M | Total Assets |
1.43B | 635.35M | 352.18M | 351.01M | 183.44M | Total Debt |
51.72M | 51.73M | 2.02M | 3.07M | 4.01M | Net Debt |
-212.82M | -3.17M | -30.65M | -197.62M | -89.07M | Total Liabilities |
109.79M | 96.25M | 35.85M | 19.07M | 14.53M | Stockholders Equity |
1.32B | 539.11M | -439.17M | -275.25M | -167.61M |
Cash Flow | Free Cash Flow | |||
-229.81M | -171.00M | -116.86M | -89.02M | -62.21M | Operating Cash Flow |
-225.97M | -166.31M | -115.20M | -88.59M | -62.03M | Investing Cash Flow |
-574.82M | -200.41M | -173.98M | -56.48M | 217.00K | Financing Cash Flow |
1.01B | 388.94M | 121.96M | 252.68M | 114.57M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $2.04B | 48.01 | -0.53% | ― | 27.28% | -101.63% | |
68 Neutral | $11.05B | 33.69 | 14.16% | ― | 24.81% | 33.67% | |
54 Neutral | $3.55B | ― | -214.50% | ― | 29.01% | 23.93% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
45 Neutral | $3.14B | ― | -32.02% | ― | ― | -0.12% | |
38 Underperform | $3.33B | ― | -74.17% | ― | ― | -43.10% |
On February 24, 2025, Crinetics Pharmaceuticals announced the appointment of Tobin Schilke as Chief Financial Officer, effective February 28, 2025. Mr. Schilke brings over 25 years of global pharmaceutical experience, having previously transformed biotech companies into commercial organizations. His appointment is seen as pivotal as Crinetics prepares for its first commercial launch and advances its development pipeline. The move is expected to accelerate Crinetics’ growth objectives and create long-term value for stakeholders.
At the J.P. Morgan Healthcare Conference in January 2025, Crinetics Pharmaceuticals outlined its 2025 priorities, including increasing commercial readiness for the potential U.S. launch of paltusotine, pending FDA approval, and advancing clinical development of atumelnant. These efforts reflect Crinetics’ strategic focus on endocrine conditions, aiming to position the company as a leader in this niche market by enhancing patient access to innovative treatments.
Crinetics Pharmaceuticals announced positive topline results from its Phase 2 study of atumelnant, an ACTH receptor antagonist candidate for treating congenital adrenal hyperplasia (CAH). The study showed significant reductions in key biomarkers and improvements in clinical signs, supporting the initiation of a Phase 3 trial. With atumelnant being well-tolerated and showing no severe adverse events, Crinetics aims to advance its development, furthering its strategy to become a leading global endocrine company.
Crinetics Pharmaceuticals has appointed Isabel Kalofonos as the Chief Commercial Officer to lead the commercial strategy for launching paltusotine, an innovative treatment for acromegaly. With over 20 years of experience in the pharmaceutical and biotech industry, Kalofonos’s appointment suggests a strategic move by Crinetics to strengthen its market position and enhance its pipeline commercialization efforts, potentially impacting stakeholders by advancing new treatments in the endocrine disorders sector.